Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 10.6a

Immunosuppression Use for Induction, 2000 to 2009

Recipients with Intestine Transplants

  Year of Transplant
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Transplants 82 113 107 116 152 178 175 198 185 180
With Immunosuppression Info 80 112 106 116 149 167 169 194 182 175
Induction Drugs
ALG 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Atgam/NRATG/NRATS 1.3% 0.0% 0.9% 1.7% 2.7% 1.8% 0.6% 0.5% 0.0% 1.1%
OKT3 5.0% 6.3% 2.8% 1.7% 1.3% 3.6% 14.2% 17.5% 15.4% 21.1%
Thymoglobulin 0.0% 12.5% 31.1% 45.7% 18.8% 15.6% 18.9% 23.7% 33.5% 41.7%
Zenapax 55.0% 24.1% 12.3% 17.2% 12.8% 13.8% 17.2% 9.8% 8.2% 4.0%
Simulect 12.5% 13.4% 13.2% 1.7% 0.7% 3.0% 3.0% 2.1% 0.5% 1.7%
Campath 0.0% 0.0% 1.9% 8.6% 19.5% 22.2% 21.3% 13.4% 18.1% 12.0%
No Induction Drugs Recorded 31.3% 43.8% 39.6% 25.0% 45.6% 45.5% 40.8% 51.0% 40.1% 41.7%


Source: OPTN/SRTR Data as of October 1, 2010.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.